Tuesday, April 18, 2006

Breast Cancer Breakthrough

Good news for women: A large government sponsored study of nearly 20,000 postmenopausal women found that raloxifene (marketed under the name of Evista) reduces their chance of developing breast cancer as effectively as tamoxifen, the only drug previously shown to reduce the risk, but is less likely to cause serious side effects such as uterine cancer and blood clots.

Because an estimated 500,000 women use raloxifene to reduce the risk of osteoporosis, many will be more comfortable using it for breast cancer protection, several experts predicted.

"It's terrific," said Susan Love, a breast cancer expert at the University of California at Los Angeles. "This gives us another drug that we can use to prevent breast cancer that is less risky than the only other drug we had."

Several experts, however, urged caution, saying that the advantage of raloxifene remains unclear and that more research is needed to prove the drug reduced the overall risk over longer periods.


Jason Walker said...

Hello, I'd like to present you interesting articles about this disease:
Breast Cancer
Breast Cancer: Trends and Incidence
Breast Cancer: Risk Factors
Breast Cancer: Effective Universal Preventive Interventions
Breast Cancer: Effective Selective Preventive Interventions
Breast Cancer: Effective Indicated Preventive Interventions
Breast Cancer: Practice and Policy Implications
Breast Cancer: Future Directions

Anonymous said...

» International Trial Of Novel Breast Cancer Drug
14/12/06 07:03 from Breast cancer blog from medicineworld.org
A clinical trial of a new targeted breast cancer drug, led by
physicians at Massachusetts General Hospital (MGH) Cancer
Center, has begun enrolling patients. The TEACH (Tykerb
Evaluation After CHemotherapy) trial will investigate ...

For useful content on breast cancer awareness prevention tips, breast cancer rate statistics and cancer risk increase weight gain: check
the url is http://breast-cancer1.com